Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. (January 2017)

• Record Type: Journal Article
• Authors: McCubrey, James A.; Lertpiriyapong, Kvin; Fitzgerald, Timothy L.; Martelli, Alberto M.; Cocco, Lucio; Rakus, Dariusz; Gizak, Agnieszka; Libra, Massimo; Cervello, Melchiorre; Montalto, Guiseppe; Yang, Li V.; Abrams, Stephen L.; Steelman, Linda S.
• Is Part Of: Advances in biological regulation. Volume 63(2017)
• Page Start: 32
• Page End: 48
• Publication Date: 2017-01
• Subjects: TP53 -- miRs -- MDM2 -- Nutlin-3 chemosensitivity -- Cellular senescence -- Invasion -- Metastasis; Cellular control mechanisms -- Periodicals; Biological control systems -- Periodicals; Molecular biology -- Periodicals; Periodicals; 571.74
• DOI: 10.1016/j.jbior.2016.10.001
• Languages: English
• ISSNs: 2212-4926

Abstract

Abstract: TP53 is a critical tumor suppressor gene that regulates cell cycle progression, apoptosis, cellular senescence and many other properties critical for control of normal cellular growth and death. Due to the pleiotropic effects that TP53 has on gene expression and cellular physiology, mutations at this tumor suppressor gene result in diverse physiological effects. T53 mutations are frequently detected in numerous cancers. The expression of TP53 can be induced by various agents used to treat cancer patients such as chemotherapeutic drugs and ionizing radiation. Radiation will induce Ataxia telangiectasia mutated (ATM) and other kinases that results in the phosphorylation and activation of TP53. TP53 is also negatively regulated by other mechanisms, such as ubiquitination by ligases such as MDM2. While TP53 has been documented to control the expression of many "classical" genes ( e.g ., p21 Cip−1, PUMA, Bax) by transcriptional mechanisms for quite some time, more recently TP53 has been shown to regulate microRNA (miR) gene expression. Different miRs can promote oncogenesis (oncomiR) whereas others act to inhibit tumor progression (tumor suppressor miRs). Targeted therapies to stabilize TP53 have been developed by various approaches, MDM2/MDM4 inhibitors have been developed to stabilize TP53 in TP53-wild type (WT) tumors. In addition, small molecules have been isolated that will reactivate certain mutant TP53s. Both of these types of inhibitors are in clinical trials. Understanding the actions of TP53 may yield novel approaches to suppress cancer, aging and other health problems.